Lars Lund-Roland, ELAR Consulting (Chairman)
Lars has broad leadership, marketing and business background and currently works as a business and management consultant. Among other responsibilities, he is Norwegian business lead for Scandinavian Development Services AB, a Nordic multi-disciplinary strategic drug and medical device development company. Lars has been Managing Director of MSD Norway (Merck & Co Inc. subsidiary) for 10 years and has more than twenty-five years’ experience from various executive positions within marketing and sales at Merck, as well as CEO of Bringwell AB(pub), a Nordic life science company listed in Stockholm. He also serves as Chairman of the Board at SonoClear AS and Palion Medical AS and as a non-executive director at Vaccibody AS. He holds a BSc degree in nursing, a graduate diploma in business and administration from the BI Norwegian Business School and Senior Executive Certificates from Colombia University and Harvard Business School.
Ingrid Dynna, NoMy, Norwegian Mycelium (Co-founder and CEO)
Ingrid is the co-founder and CEO of Norwegian Mycelium (NoMy), an R&D company re-imagining a greener and more circular world of new foods, feeds and materials.
Before joining NoMy, Ingrid spent nearly 16 years at Google where she held a broad set of positions across 4 different markets, ranging from starting up the Norwegian online sales team in Dublin, working as the right hand of Google’s global Chief Business Officer in London and California, to launching and managing YouTube in Norway.
Ingrid holds a Master in European Business from EDHEC, France and has extensive working experience within marketing/sales, strategy and business development. She is currently an executive board member in Amedia and holds several advisory board positions.
Ingrid is passionate about how new innovation and technology can help solve big challenges, particularly when it comes to life science and sustainability.
Jan Terje Andersen, University of Oslo/Oslo University Hospital (Professor)
Jan Terje is a professor in biomedical innovation at the Department of Pharmacology, the Faculty of Medicine at the University of Oslo, and a research group leader at Oslo University Hospital’s Department of Immunology. He is heading the Laboratory of Adaptive Immunity and Homeostasis, which is studying the cellular processes and molecular interplay underlying the functions of the two most abundant proteins in blood, albumin and IgG. By combining structural and biophysical approaches with cellular and in vivo studies, the laboratory is using this in-depth knowledge to design novel albumin and antibody molecules with improved functions. The laboratory is highly innovative and is the research group at the University of Oslo and Oslo University Hospital with most registered innovations at the technology transfer office Inven2. The laboratory is extensively collaborating with biotech and pharmaceutical companies. Jan Terje Andersen has obtained the Fridtjof Nansen Prize for Early Career Achievements, Oslo University Hospital Early Career Award and is a member of The Young Academy of Norway.
Jonas Hallén, Arxx Therapeutics (Chief Medical Officer, Co-Founder)
Jonas is the Chief Medical Officer and Co-Founder of Arxx Therapeutics, a pre-clinical stage biotech company developing a monoclonal antibody for rare fibrotic diseases. Prior to joining Arxx, Jonas was a Medical Director in Region Europe at Novartis. At Novartis, he also served as Real-World Evidence Lead in the Nordics where he was responsible for external real-world evidence collaborations with academic institutions and private companies across the Nordics. Before his tenure at Novartis, he was the Clinical Program Leader at Pronova BioPharma. Jonas began his industry career at Boehringer Ingelheim in the medical group where he became the Nordic Therapeutic Area Director for cardiovascular products. Jonas has been on the board of the Pharmaceutical Physician Association in Norway (a specialty branch of the Norwegian Medical Association). He is an MD from the University of Copenhagen and has a PhD in cardiovascular disease from the University of Oslo. His research interests span cardiovascular biomarkers, clinical trial design and drug development.
Katrine Malmer-Høvik, SANDS (Lawyer)
Katrine is a specialized lawyer with more than 20 years of experience within industrial rights (patent, trademark and design), copyright, marketing and contract law. She also provides advice on legal aspects related to personal data protection, including implementation and compliance with the General Data Protection Regulation (GDPR). She regularly litigates before the courts; in recent years she has had a particular focus on patent litigation. She assists clients in preparation and handling of commercial agreements, including consortium agreements, project agreements, and license and technology transfer agreements.
She has experience from NIPO (the Norwegian Industrial Property Office), where she worked as a legal adviser for 9 years before joining SANDS in 2008.
She has assisted many innovative companies within different technological fields such as life science, health, aquaculture, fisheries, energy, mobility and creative industry. Knowledge about various industries provides useful insight for counselling both in drafting agreements and IP strategies, as well as in order to administrate the competitive advantage an IP right consists of.
Katrine graduated as cand. jur from the University of Oslo in 1998, and completed studies in industrial rights, comparative law and human rights at Université Montesquieu, Bordeaux, France in 1996.
She gives lectures in intellectual property issues and contract law and is frequently used as a lecturer at the Norwegian Industrial Property Office.
Lotte Skolem, Aker BioMarine AS (Director Product & Technology)
Lotte is Director of Product & Technology in Aker BioMarine, a biotech innovator and Antarctic krill-harvesting company, developing krill-based ingredients for pharmaceutical, nutraceutical, aquacultural, and animal feed applications. Lotte works with the company’s innovation strategy, portfolio and strategic innovation projects. Prior to joining Aker BioMarine, Lotte was a project manager at Boston Consulting Group, where she worked on strategy development and technology within MedTech, Pharma and Energy. She holds a master’s degree in Nanotechnology from NTNU in Trondheim and enjoys working in the intersection between R&D and business to drive new innovations that can make a difference.
Øivind Enger, Sarsia Seed Management AS (Partner)
Øivind is a partner in Sarsia Management AS, managing two early stage investment funds. He holds a Ph.D in microbiology from the University of Bergen and has over 13 years of research experience in marine microbial ecology, molecular microbiology and fish disease. Øivind has TTO experience with commercialising research based projects in biology, aquaculture, medicine and biotechnology. He has 16 years of experience from investment fund management, and experience from a number of BoD positions in life science based companies in various stages of development.
Per Morten Sandset, University of Oslo (Vice-rector & professor)
Per Morten holds an MD and PhD from the University of Oslo (UiO). He is a board certified specialist of internal medicine and hematology. He has previously had leading positions as department head, division leader and head of research at the Oslo University Hospital (OUH) and director of research, innovation and education with the southeastern Norway Regional Healthy Authority. He is currently vice-rector and professor at UiO with responsibilities for research and innovation and leads the professional development of the new life science building of the university. He has an adjunct position as a consultant and research leader at the department of hematology and the research institute of internal medicine at the OUH.
Sandset has supervised 31 PhD students. He is mainly involved in basal and clinical/epidemiological studies on the mechanism of thrombosis, along with prophylaxis and treatment of arterial and venous thrombosis. He is currently involved in cell-based gene therapy for inherited coagulation factor deficiencies and investigating the link between cancer and thrombosis.
Frode Nakkim, Bayer AS (Communications, Public Affairs and Sustainability Manager)
Frode serves as communications manager at Bayer, and is responsible for the company’s government and politics contact, media contact, external and internal communication along with sustainability. He has 13 years of experience from communication agencies and international companies, and 20 years of experience as a journalist and editorial director in national media. He also takes on assignments as meeting leader and has led several strategic communication projects. Frode is concerned with interaction across sectors, value creation and societal benefits created through public-private partnerships, and facilitation of innovation and business development in Norway. Bayer conducts research, development and production with large investments in Norway and is among the most important companies in the pharmaceutical industry. In addition, Bayer is a full-fledged life science company with significant activities within Crop Science.